{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:50Z","timestamp":1786982750507,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Samsung Bioepis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40261-023-01284-5","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T03:02:21Z","timestamp":1692846141000},"page":"579-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-6787","authenticated-orcid":false,"given":"H\u00e9ctor","family":"Corominas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R. Fraser","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Thaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"issue":"9602","key":"1284_CR1","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861\u201374.","journal-title":"Lancet"},{"key":"1284_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3389\/fimmu.2020.00589","volume":"11","author":"P Mehta","year":"2020","unstructured":"Mehta P, Manson JJ. What is the clinical relevance of TNF inhibitor immunogenicity in the management of patients with rheumatoid arthritis? Front Immunol. 2020;11:589.","journal-title":"Front Immunol"},{"issue":"3","key":"1284_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14712598.2019.1566456","volume":"19","author":"E Pelechas","year":"2019","unstructured":"Pelechas E, Drosos AA. Etanercept biosimilar SB-4. Expert Opin Biol Ther. 2019;19(3):173\u20139.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"1284_CR4","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/rheumatology\/kex269","volume":"56","author":"P Emery","year":"2017","unstructured":"Emery P, Vencovsk\u00fd J, Sylwestrzak A, et al. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology. 2017;56(12):2093\u2013101.","journal-title":"Rheumatology"},{"key":"1284_CR5","doi-asserted-by":"crossref","unstructured":"Gisbert JP, Gaffney K, Young D, Ebbers HC, Girolomoni G. Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi): a multidisciplinary perspective. Expert Opin Biol Ther. 2022 (just-accepted).","DOI":"10.1080\/14712598.2022.2012146"},{"issue":"1","key":"1284_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/art.40336","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB 5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70(1):40\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"1284_CR7","first-page":"S459","volume":"15","author":"A Dignass","year":"2022","unstructured":"Dignass A, Gisbert J, Freudensprung U, Addison J. P434 The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn\u2019s disease. J Crohns Colitis. 2022;15(Suppl 1):S459\u201360.","journal-title":"J Crohns Colitis"},{"key":"1284_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/BTT.S124476","volume":"11","author":"JR Tesser","year":"2017","unstructured":"Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biol Targets Ther. 2017;11:5.","journal-title":"Biol Targets Ther"},{"issue":"1","key":"1284_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/10717544.2019.1587043","volume":"26","author":"BJ van den Bemt","year":"2019","unstructured":"van den Bemt BJ, Gettings L, Doma\u0144ska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384\u201392.","journal-title":"Drug Deliv"},{"issue":"3","key":"1284_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40744-020-00216-5","volume":"7","author":"N Rekaya","year":"2020","unstructured":"Rekaya N, Vicik SM, Hulesch BT, McDonald LL. Enhancement of an auto-injector device for self-administration of etanercept in patients with rheumatoid arthritis confers emotional and functional benefits. Rheumatol Ther. 2020;7(3):537\u201352.","journal-title":"Rheumatol Ther"},{"key":"1284_CR11","unstructured":"EMA. Guideline on similar biological medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Date accessed: 22 Jun 2022."},{"key":"1284_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/DDDT.S224103","volume":"14","author":"D Shin","year":"2020","unstructured":"Shin D, Kim Y, Go A, Velinova M. Comparison of the pharmacokinetics, safety, and tolerability of the autoinjector (AI) and pre-filled syringe (PFS) of SB4 in healthy subjects. Drug Des Dev Ther. 2020;14:43.","journal-title":"Drug Des Dev Ther"},{"key":"1284_CR13","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.2147\/DDDT.S169082","volume":"12","author":"D Shin","year":"2018","unstructured":"Shin D, Lee Y, Jeong D, Ellis-Pegler R. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects. Drug Des Dev Ther. 2018;12:3799.","journal-title":"Drug Des Dev Ther"},{"issue":"9","key":"1284_CR14","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s12325-019-01027-z","volume":"36","author":"YH Rho","year":"2019","unstructured":"Rho YH, Rychlewska-Ha\u0144czewska A, \u015aliwowska B, Kim TH. Usability of prefilled syringe and autoinjector for SB4 (an etanercept biosimilar) in patients with rheumatoid arthritis. Adv Ther. 2019;36(9):2287\u201395.","journal-title":"Adv Ther"},{"issue":"3","key":"1284_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/03007995.2018.1560211","volume":"35","author":"J Ghil","year":"2019","unstructured":"Ghil J, Zieli\u0144ska A, Lee Y. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis. Curr Med Res Opin. 2019;35(3):497\u2013502.","journal-title":"Curr Med Res Opin"},{"issue":"65","key":"1284_CR16","volume":"32","author":"MC Kilic","year":"2018","unstructured":"Kilic MC, Calik BB, Cobankara V, Balkarli A. The relationship between hand function and activity performance in patients with rheumatoid arthritis. Age. 2018;32(65): 50.7-9.9.","journal-title":"Age"},{"key":"1284_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/PPA.S50583","volume":"8","author":"F Schwarzenbach","year":"2014","unstructured":"Schwarzenbach F, Trong MD, Grange L, et al. Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis. Patient Prefer Adherence. 2014;8:199.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"1284_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40744-016-0048-9","volume":"3","author":"K Thakur","year":"2016","unstructured":"Thakur K, Biberger A, Handrich A, Rezk MF. Patient perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: findings from a patient survey in Europe. Rheumatol Ther. 2016;3(2):245\u201356.","journal-title":"Rheumatol Ther."},{"issue":"1","key":"1284_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40744-016-0035-1","volume":"3","author":"K Thakur","year":"2016","unstructured":"Thakur K, Biberger A, Handrich A, Rezk MF. Perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: a new European Union-approved etanercept biosimilar (Benepali\u00ae) versus etanercept (Enbrel\u00ae)-findings from a nurse survey in Europe. Rheumatol Ther. 2016;3(1):77\u201389.","journal-title":"Rheumatol Ther"},{"key":"1284_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/PPA.S169339","volume":"12","author":"B Tischer","year":"2018","unstructured":"Tischer B, Mehl A. Patients\u2019 and nurses\u2019 preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Prefer Adherence. 2018;12:1413.","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"1284_CR21","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s12325-017-0523-x","volume":"34","author":"M Egeth","year":"2017","unstructured":"Egeth M, Soosaar J, Nash P, et al. Patient and healthcare professionals preference for Brenzys vs. Enbrel autoinjector for rheumatoid arthritis: a randomized crossover simulated-use study. Adv Ther. 2017;34(5):1157\u201372.","journal-title":"Adv Ther"},{"issue":"2","key":"1284_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40744-019-0144-8","volume":"6","author":"S Fenwick","year":"2019","unstructured":"Fenwick S, Thakur K, Munro D. Nurse and patient perceptions and preferences for subcutaneous autoinjectors for inflammatory joint or bowel disease: findings from a European survey. Rheumatol Ther. 2019;6(2):195\u2013206.","journal-title":"Rheumatol Ther"},{"key":"1284_CR23","doi-asserted-by":"crossref","unstructured":"Karlsdottir K, Gunnarsdottir AI, Grondal G, et al. A patients\u2019 perspective towards the injection devices for Humira\u00ae and Imraldi\u00ae in a nationwide switching program; 2022.","DOI":"10.3389\/fmed.2022.799494"},{"key":"1284_CR24","doi-asserted-by":"crossref","unstructured":"Maucksch C, Aries PM, Zinke S, M\u00fcller-Ladner U. Patient satisfaction with the etanercept biosimilar SB4 device, among rheumatoid arthritis and spondyloarthropathy patients\u2014a German observational study. Open Rheumatol J. 2020;14(1).","DOI":"10.2174\/1874312902014010007"},{"issue":"Suppl 1","key":"1284_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/ecco-jcc\/jjab232.561","volume":"16","author":"A Dignass","year":"2021","unstructured":"Dignass A, Gisbert J, Bossa F, et al. P434 The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn\u2019s disease. J Crohns Colitis. 2021;16(Suppl 1):418. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab232.561.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"1284_CR26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.clinthera.2006.10.006","volume":"28","author":"A Kivitz","year":"2006","unstructured":"Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619\u201329.","journal-title":"Clin Ther"},{"key":"1284_CR27","unstructured":"EMA. Benepali summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benepali-epar-product-information_en.pdf. Date accessed: 14 Jun 2022."},{"key":"1284_CR28","unstructured":"EMA. Imraldi summary of product characteristics. Accessed Jun-14, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imraldi-epar-product-information_en.pdf. Date accessed: 14 Jun 2022."},{"key":"1284_CR29","unstructured":"EMA. Humira summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf. Date accessed: 15 Jun 2022"},{"key":"1284_CR30","unstructured":"EMA. Enbrel summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enbrel-epar-product-information_en.pdf. Date accessed: 15 Jun 2022."},{"key":"1284_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33393\/dti.2021.2342","volume":"15","author":"S Losi","year":"2021","unstructured":"Losi S, Berra CCF, Fornengo R, Pitocco D, Biricolti G, Federici MO. The role of patient preferences in adherence to treatment in chronic disease: a narrative review. Drug Target Insights. 2021;15:13\u201320. https:\/\/doi.org\/10.33393\/dti.2021.2342.","journal-title":"Drug Target Insights"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01284-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01284-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01284-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T07:22:58Z","timestamp":1693898578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01284-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1284"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01284-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"20 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for medical writing was sponsored by Samsung Bioepis Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H.C. received consultancy\/advisory boards fees, lecturing\/research support\/education support from MSD, Lilly, AbbVie, Pfizzer, Gebro, BMS, Roche, Sanofi, Novartis, UCB, Celgene, Amgen, Biogen, Khern, Galapagos, Fresenius, and Chiesi. D.Y. declares no conflict of interest to disclose. F.C. received consultancy\/lecturing\/research support\/education support from AbbVie, Amgen, AstraZeneca, Biogen, Celltrion, Galapagos, Gilead, GlaxoSmithKline, Janssen, MSD, Nestle Health Sciences, Norgine, Pfizer, Pharmacosmos, Samsung Bioepis, Shield Therapeutics, Takeda, and Vifor. Y.B. has received consulting\/advisory board fees from AbbVie, Amgen, Biogaran, Biogen, Boehringer Ingelheim, Celltrion, Ferring, Fresenius Kabi, Gilead, Hospira, Iterative Scopes, Janssen, Lilly, Mayoli Spindler, Merck, MSD, Norgine, Pfizer, Roche, Sandoz, Sanofi, Shire, Takeda, Tillotts, and UCB. A.A. has received consulting\/advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, and Takeda; speaker\u2019s fees from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, and Tigenix; research support from MSD, Takeda, Pfizer, and Biogen. J.K. is an employee of Samsung Bioepis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This review is based on previously conducted studies and does not contain any studies with human participants or animals performed by the author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"HC, DY, JRFC, UB, AA, DT and JK contributed to the conception, drafts, and final version of this article, and gave approval of the version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}